MedTrace Logo

A Study of of MORAb-004 in Subjects With Solid Tumors

NCT00847054 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2014-07-16

No results posted yet for this study

Summary

The purpose of this study is to determine the safety of multiple intravenous infusions of MORAb-004.

Conditions

Interventions

DRUG

MORAb-004 (monoclonal antibody to TEM1)

Intravenous administration

Sponsors & Collaborators

  • Morphotek

    lead INDUSTRY

Principal Investigators

  • Susan Weil, MD · Morphotek

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2014-04-30
Completion
2014-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00847054 on ClinicalTrials.gov